Inventia Recalls 25,027 Chlorthalidone Bottles Nationwide

Inventia Healthcare has recalled more than 25,000 bottles of its 25-milligram chlorthalidone tablets in two nationwide recalls after the pills failed dissolution tests, meaning they may not break down at the intended rate and could affect how the drug is absorbed. The recalls cover batches expiring in April 2027 and are classified by the FDA as Class II, indicating temporary or medically reversible health effects are possible, while serious harm is considered unlikely. People taking chlorthalidone should check with a pharmacist or health care provider about whether their medication is affected and should not stop taking it without medical guidance.